CCN2 and hepatocellular carcinoma: The synergistic effect of sorafenib, U0126, or CCN2 silencing in oxaliplatin-resistant HCC cells also resulted in inducing a significantly decreased IC50 of HCC cells to oxaliplatin (Fig. 6b).